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Genomic  uracil  is  normally  processed  essentially  error-free  by  base  excision  repair  (BER), with  mismatch
repair (MMR)  as  an apparent  backup  for  U:G  mismatches.  Nuclear  uracil-DNA  glycosylase  UNG2  is  the
major enzyme  initiating  BER  of uracil  of U:A  pairs  as  well  as U:G  mismatches.  Deﬁciency  in UNG2  results
in several-fold  increases  in  genomic  uracil  in  mammalian  cells.  Thus,  the  alternative  uracil-removing
glycosylases,  SMUG1,  TDG  and  MBD4  cannot  efﬁciently  complement  UNG2-deﬁciency.  A  major  function
of  SMUG1  is probably  to remove  5-hydroxymethyluracil  from  DNA  with  general  back-up  for  UNG2  as
a  minor  function.  TDG  and  MBD4  remove  deamination  products  U  or T mismatched  to G in CpG/mCpG
contexts,  but  may  have equally  or more  important  functions  in  development,  epigenetics  and  gene  regu-
lation.  Genomic  uracil  was  previously  thought  to arise  only  from  spontaneous  cytosine  deamination  and
incorporation  of  dUMP,  generating  U:G  mismatches  and  U:A pairs,  respectively.  However,  the identiﬁca-
tion  of activation-induced  cytidine  deaminase  (AID)  and  other  APOBEC  family  members  as  DNA-cytosine
deaminases  has  spurred  renewed  interest  in  the  processing  of  genomic  uracil.  Importantly,  AID  triggers
the  adaptive  immune  response  involving  error-prone  processing  of  U:G  mismatches,  but  also  contributes
to  B-cell  lymphomagenesis.  Furthermore,  mutational  signatures  in a substantial  fraction  of  other  human
cancers  are consistent  with  APOBEC-induced  mutagenesis,  with  U:G  mismatches  as prime  suspects.
Mutations  can  be caused  by  replicative  polymerases  copying  uracil  in U:G  mismatches,  or by  translesion
polymerases  that  insert incorrect  bases  opposite  abasic  sites  after  uracil-removal.  In addition,  kataegis,
localized  hypermutations  in one  strand  in  the  vicinity  of  genomic  rearrangements,  requires  APOBEC  pro-
tein, UNG2  and  translesion  polymerase  REV1.  What mechanisms  govern  error-free  versus  error  prone
processing  of  uracil  in  DNA  remains  unclear.  In conclusion,  genomic  uracil  is  an essential  intermediate  in
adaptive immunity  and  innate  antiviral  responses,  but may  also  be a fundamental  cause  of a wide  range
of  malignancies.
© 2014  The  Authors.  Published  by  Elsevier  B.V. This  is  an  open  access  article  under  the  CC  BY-NC-ND. Introduction
.1. DNA damage and base excision repair
Base excision repair (BER) corrects small base lesions in DNA
hat do not distort the structure of the DNA helix and thus pre-
ents the cytotoxicity and mutagenicity of such damage. The BER
athway was discovered by Lindahl [1]. So, 2014 marks the 40 year
nniversary for BER. A large fraction of the lesions recognized by
his pathway is caused by spontaneous chemical decay of DNA due
∗ Corresponding author. Tel.: +47 72573074; fax: +47 72576400.
E-mail address: hans.krokan@ntnu.no (H.E. Krokan).
ttp://dx.doi.org/10.1016/j.dnarep.2014.03.028
568-7864/© 2014 The Authors. Published by Elsevier B.V. This is an open access article unlicense (http://creativecommons.org/licenses/by-nc-nd/3.0/).
to hydrolytic base deamination and base loss. In addition, spon-
taneous damage occurs due to non-enzymatic reactions of bases
with natural cellular substituents, such as S-adenosylmethionine
(base methylations), reactive oxygen species (base oxidations) and
DNA replication errors [2]. Similar DNA lesions may be caused by
environmental chemicals and radiation, but the range of lesions
induced is much wider [3,4] and all known pathways of repair
must be involved in their repair. The major steps in BER comprise;
(a) damage recognition and removal; (b) strand incision and
end trimming; (c) nucleotide insertion; and (d) ligation (Fig. 1).
Importantly, several proteins involved in DNA repair also have
essential roles in adaptive immunity triggered by activation-
induced cytidine deaminase (AID). However, there are also risks
associated with mechanisms of adaptive immunity that are by
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
H.E. Krokan et al. / DNA Repair 19 (2014) 38–47 39
F amag
l d long
p itiated
P
t
A
h
t
a
oig. 1. The base excision repair (BER) pathway. BER takes place in four major steps; d
igation.  Downstream of base removal BER takes place by short patch repair (SPR) an
lace  both in proliferating and non-proliferating cells. Furthermore, when BER is in
NKP, AP-endonuclease is dispensable.
heir nature mutagenic, although normally targeted. Furthermore,
POBEC-family proteins other than AID are apparently involved in
uman carcinogenesis, also in concert with DNA repair proteins.The present review will focus on new developments in BER in
he last decade, with emphasis on processing of genomic uracil,
nd its likely role in human cancer, but will start with a general
verview of BER.e recognition and removal; strand incision and end trimming; nucleotide insertion;
 patch repair (LPR). LPR is largely restricted to proliferating cells, whereas SPR takes
 by a DNA glycosylase carrying out /-elimination followed by end-trimming by
1.2. Mammalian DNA glycosylases
BER is initiated by one of 11 known DNA glycosylases with
speciﬁcity for different base lesions, or mismatches of normal
bases. Some DNA glycosylases are highly selective, whereas others
remove a wider range of lesions. How the DNA glycosylases ﬁnd
the damaged or incorrect base and ﬂips it into the active site is
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ubject to intensive research and important results have emerged
n the last decade. DNA glycosylases are either monofunctional
those removing uracil and alkylations), bifunctional, or even
rifunctional (all removing oxidized bases). Monofunctional glyco-
ylases have DNA glycosylase activity only, whereas bifunctional
nes in addition have 3′ lyase activity that cleaves DNA 3′ of the
osition of the removed base (reviewed in [5,6]). Monofunctional
lycosylases generally use an activated water molecule as nucle-
phile to attack the C1′ carbon of the damaged nucleotide. The
ctive site of monofunctional glycosylases is generally relatively
tatic and in some cases very tight, e.g. in uracil-DNA glycosylase
ncoded by the UNG gene, thereby restricting substrate preference
7–9]. The DNA binding groove binds and sharply bends substrate
NA at the position of the damaged base, thereby aiding ﬂipping
nd positioning of the substrate base into the catalytic pocket [10].
n contrast, bifunctional glycosylases have a more ﬂexible active
ite and use the side chain -amino group of an active site lysine or
he secondary amino group of an N-terminal proline as nucleophile
o attack the glycosidic bond. In this process, the lysine or proline
f the enzyme forms a covalent bond with C1′ of the deoxyribose.
his results in ring opening and formation of a Schiff base between
he Lys/Pro-residue of the enzyme and 3′ strand cleavage by
-elimination (reviewed in [10]). Although glycosylases repairing
xidized bases are usually classiﬁed as bifunctional, OGG1 [11]
nd NEIL3 [12] appear to function largely as monofunctional under
ear physiological experimental conditions. This demonstrates
hat the glycosylase and lyase activities are not coupled. NEIL1
nd NEIL2 carry out ,-elimination in a slightly more complex
chedule than the typical bifunctional glycosylases. Thus, NEIL1
ses both an internal Lys and the N-terminal Pro to carry out
ase release and /-elimination in a concerted action. If the
ys-residue is mutated, the reaction is restricted to base removal
nd -elimination [13]. All of these reactions take place at the
ame active site that is apparently ﬂexible and allows confor-
ational changes upon substrate binding to position catalytic
esidues.
.3. Strand incision
The catalytic mechanisms of glycosylases have consequences
or the subsequent steps. Following base excision by monofunc-
ional glycosylases, the resulting “normal” abasic site (apyrimi-
inic/apurinic site; AP-site) is incised 5′ of deoxyribose phosphate
y an AP-endonuclease. The deoxyribose phosphate (dRP) gen-
rated is removed by the dRPase activity of DNA polymerase
, a major family × polymerase [14]. The action of these two
nzymes generates the substrate for gap ﬁlling and ligation.
 bifunctional DNA glycosylase (e.g. NTH1) generates 5′ phos-
hate and a 3′ phospho-a,-unsaturated aldehyde (3′ PUA) end
hat is removed by AP endonuclease (Fig. 1), thus preparing the
epair intermediate for nucleotide insertion and ligation [5,15].
owever, some glycosylases are even trifunctional and carry
ut /-elimination (NEIL1 and 2) by cleaving both 3′ and 5′
f the abasic site. They release the modiﬁed deoxyribose as an
nsaturated hydroxyaldehyde, generating 3′-phosphate and 5′-
hosphate ends ﬂanking a single nucleotide gap. In contrast
o the major AP-endonuclease of Escherichia coli, mammalian
PE1 has extremely low 3′-exonuclease activity. However, mam-
alian cells have a polynucleotide kinase/phosphatase (PNKP) with
′-exonuclease activity ∼1000-fold higher kcat/KM than that of
PE1. This PNKP removes 3′-phosphate, preparing for the DNA
olymerase step and ligation (Fig. 1). Thus, for NEIL1 and 2, AP-
ndonuclease is dispensable for strand incision and 3′-phosphate
emoval [15].air 19 (2014) 38–47
1.4. Nucleotide insertion by short-patch repair or long-patch
repair
The nucleotide insertion step can take place by either short-
patch repair (SPR), in which one nucleotide is inserted in a
one-nucleotide gap, or long-patch repair (LPR), in which a stretch
of ∼2–10 nucleotides is ﬁlled prior to ligation (reviewed in
[6,16,17]). SPR requires several specialized proteins that do not
participate in DNA replication. These include DNA polymerase ,
AP-endonuclease 1, DNA ligase III, XRCC1 and PARP1 [6], although
the latter may  not contribute in all types of BER [18]. Furthermore,
recent information indicates that DNA ligase I is the major lig-
ase also in SPR, while DNA ligase III is essential for mitochondrial
BER [19,20]. SPR is possibly the only operative BER mechanism in
non-proliferating cells and also a major BER mechanism in prolif-
erating cells. As mentioned, the dRPase domain of DNA polymerase
 removes the deoxyribose-5′-phosphate (5′-dRP) generated by
the AP-endonuclease (reviewed in [14]). This activity is essential
in SPR, but not in LPR, which largely uses replication proteins in
the downstream steps. Here, DNA polymerase  or  interacts with
the sliding clamp PCNA to ﬁll a 2–10 nucleotide gap, displacing
the old strand to create a “ﬂap” that is removed by the structure-
speciﬁc ﬂap endonuclease 1 (FEN1), then DNA ligase I seals the nick.
The PCNA clamp loading protein RPC is also required [6,17,21,22].
However, DNA polymerase , appears to insert the ﬁrst nucleotide
also in LPR in cell extracts [23], and possibly in vivo as well [24].
Furthermore, at least in non-proliferating cells, DNA polymerase 
may  readily insert two nucleotides, thus blurring the operative dis-
tinction between SPR and LPR [25]. Mutations in the gene encoding
the WRN  protein, a RecQ family helicase, cause the Werner syn-
drome characterized by early aging and increased cancer risk. WRN
helicase is a large protein with multiple roles in genome integrity,
including telomere maintenance. WRN  also has functions in the
BER pathway, where it interacts with several proteins and stimu-
lates the activity of FEN1. It may  be particularly important in repair
of oxidative damage (reviewed in [26]). At least two  other proteins
in the RecQ helicase family, RECQ5 and BLM, also appear to have
roles in BER [27,28]. Undoubtedly, other proteins contribute to and
modulate various steps of the BER mechanisms and their regula-
tion. There are many candidates, but their distinct roles require
more work.
1.5. BER in mitochondria
The mitochondrial genome is also subject to DNA repair, includ-
ing BER, single strand break repair, mismatch repair, homologous
recombination and possibly non-homologous end-joining, but not
nucleotide excision repair (reviewed in [29,30]). Mitochondrial
DNA glycosylases are usually splice variants or other isoforms
of the corresponding nuclear proteins, as ﬁrst demonstrated for
UNG1 (mitochondrial) and UNG2 (nuclear) uracil-DNA glycosy-
lases [31]. Mitochondria have DNA glycosylases initiating repair
of uracil, alkylated and oxidized bases. They also contain AP-
endonuclease APE1. The only DNA polymerase in mitochondria,
DNA polymerase , also has dRPase activity, like DNA polymerase
 (reviewed in [29,30]). Although initially thought to carry out
SPR only, it is now known that mitochondria can carry out both
SPR and LPR [32,33,34]. SPR is thought to be initiated by a DNA
glycosylase, followed by APE1 for strand cleavage, DNA poly-
merase  for nucleotide insertion and dRP-removal and DNA
ligase III for sealing of the nick. Following DNA incision, LPR has
been shown to require FEN1 and DNA2 for strand displacement
and removal of the ﬂap, followed by ligation by DNA ligase III
[29,30,35]. However, a subsequent study suggested that EXOG,
rather than FEN1/DNA2, provides the critical 5′-exonuclease activ-
ity for mtBER [36]. Notably, mitochondrial DNA glycosylases and
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PE1 are markedly inhibited by two abundant mitochondrial pro-
eins, the transcription factor and DNA packaging protein TFAM
37] and the mitochondrial single-strand binding protein SSBP1
mtSSB) [38]. It is likely that TFAM restricts accessibility of BER
roteins to the site of damage by mediating higher order struc-
ures in DNA. Translocation of p53 into mitochondria subsequent
o oxidative stress may  thus be a means to facilitate repair of oxida-
ive base damage since p53 abrogates binding of TFAM to oxidized
ases. Moreover, SSBP1 may  facilitate recruitment of mitochondrial
NG1 and NEIL1 as well as APE1 to damage sites in mitochondrial
sDNA, but delay damage processing until the dsDNA conformation
s restored to avoid formation of DSBs [38].
. Generation and processing of genomic uracil
.1. Genomic uracil
The idea that uracil may  be present in DNA originates from the
nding that cytosine slowly deaminates to form uracil, both as base,
ucleoside, nucleotide and in DNA [39,40,41]. In double stranded
NA, this would give rise to mutagenic U:G mismatches. Impor-
antly, the rate of deamination in double-stranded DNA is <1% of
hat of single-stranded DNA [40]. The lack of information on the
ize of the fraction of single stranded DNA in living cells has made
alculation of the rate of cytosine deamination in genomic DNA
ifﬁcult [42]. Later, incorporation of dUTP into bacterial [43] and
ammalian cells [44] DNA during replication was demonstrated.
his results in U:A pairs that are not directly mutagenic, but may
ive rise to mutagenic abasic sites. The interest in genomic uracil
ncreased tremendously after it was demonstrated that activation-
nduced cytidine deaminase (AID or AICDA) as well as several other
embers of the APOBEC family are apparently DNA-cytosine deam-
nases rather than RNA-cytosine deaminases [45,46]. In spite of
he potential importance of AID and genomic uracil in adaptive
mmunity, as well as the likely roles of AID and other APOBEC
roteins as mutators in cancer development, the knowledge of
he amounts, sources and localization of genomic uracil is lim-
ted. One reason for this is that different methods to quantify
enomic uracil have given widely differing results (over 1000-
old), even when using potentially sophisticated LC–MS methods.
mong the many reasons for these inconsistencies are failure to dis-
riminate between the relatively abundant and naturally occurring
sotope [13C]-dCyd (which is isobaric with dUrd), prolonged nucle-
se degradation which generates dUrd from dCyd, and dUrd from
ontaminating sources (see [47] and references therein). Recent
ork using a well-controlled LC–MS/MS method indicates that
he global content of genomic uracil is ∼400–600 per mammalian
iploid genome in UNG-proﬁcient cells and 8–10-fold higher in
NG-deﬁcient cells [47], although recent work in our laboratory
Pettersen et al., unpublished) indicates a somewhat higher average
enomic uracil-content in cancer cell lines. The high level of uracil
n UNG-deﬁcient cells suggests that other uracil-DNA glycosy-
ases, SMUG1 (single strand-selective monofunctional Uracil-DNA
lycosylase), TDG (T/U-mismatch DNA glycosylase) and MBD4
methyl-binding domain 4 protein), as well as mismatch repair
of U:G), cannot efﬁciently complement the lack of UNG. Although
he level of genomic uracil measured using this method is lower
han previous estimates, it is high compared to the estimated rates
f spontaneous deamination of cytosine (∼200 per mammalian
enome per day) [42]. The steady state level of ∼400–600 uracils
er genome may  suggest contribution from sources other than
pontaneous deamination, or limited repair efﬁciency. Possibly,
ncorporation of dUMP is much more abundant than deamination of
ytosine in proliferating cells, but in the absence of methods to dis-
riminate between genomic U:G and U:A, this remains speculative.
nfortunately, the localization and context of genomic uracils areair 19 (2014) 38–47 41
not yet known, except for their accumulation as U:G mismatches
in variable and switch regions of Ig-genes in antigen-stimulated
B-cells [48].
2.2. Processing of genomic uracil by BER, with MMR  as an
apparent backup
The original discovery of bacterial uracil-DNA glycosylase (Ung)
as an enzyme that releases uracil from DNA [1] precipitated exten-
sive work on uracil-DNA glycosylases from different organisms
(reviewed in [22,42,49–51]. The ﬁrst mammalian DNA glycosylase
gene to be identiﬁed, human UNG, was  shown to be closely related
to the ung gene in E. coli, hence named UNG [52,53]. The UNG gene
encodes both the nuclear form, UNG2, and the mitochondrial form,
UNG1. These are generated using different promoters and alter-
native splicing, resulting in different N-terminal sequences, but
identical catalytic domains [22,31]. UNG2 is cell cycle regulated
with the highest expression during the early and middle S-phase,
during which it is sequentially triple-phosphorylated and ubiqui-
tylated [54]. UNG2 interacts with replication protein A (RPA) and
proliferating cell antigen (PCNA) through its unique N-terminal
region, and a large fraction of it is located in replication foci during
S-phase [55]. Using isolated nuclei as model system, incorporated
dUMP was found to be very rapidly removed from DNA [44,55].
The rate of removal was strongly reduced by UNG-antibodies [55]
and in nuclei from Ung−/− mouse cells [56], demonstrating that
rapid post-replicative repair of incorporated uracil requires UNG2.
Less is known about proteins interacting with UNG1, which essen-
tially constitutes the catalytic domain. The structure and catalytic
function of the compact catalytic domain of UNG-proteins has been
extensively studied and reviewed [6,10,21,22,51,57,58]. UNG1 and
UNG2 are both highly selective for uracil in DNA  and have a mod-
erate to weak preference for uracil in single stranded DNA over
U:G mismatches and U:A pairs, with turnover rates in the order of
103 per min  [59]. In spite of the strong preference for uracil, UNG2
is also a major glycosylase for removal of 5-ﬂuorouracil in intact
cells, but this activity neither enhances or reduces the cytotoxicity
of 5-ﬂuorouracil, making repair-induced fragmentation of DNA as
a cause of toxicity unlikely [60]. UNG also has weak activity with
some oxidized bases derived from cytosine, but the signiﬁcance of
this remains uncertain [61]. The high activity of UNG2 with single
stranded DNA is intriguing, since BER requires a complementary
strand. However, RPA has been shown to inhibit the single-stranded
abasic endonuclease activity of APE1 [62]. RPA might thus serve
dual role in recruiting UNG2 to single-strand regions to promote
uracil removal while concomitantly suppressing further process-
ing of the AP-site until the dsDNA conformation is restored and a
template becomes available for BER.
SMUG1 was originally discovered as a single strand selective
uracil-DNA glycosylase in Xenopus laevis [63] but at least in mam-
malian cells, SMUG1 uses double stranded DNA more efﬁciently
[59,64]. SMUG1 has a very low turnover number compared with
UNG, but like UNG, it removes uracil both from U:G  mismatches
and U:A pairs [59]. SMUG1 is a single domain protein structurally
related to UNG and TDG, with a central parallel -sheet surrounded
by -helices. At the amino acid sequence level UNG, TDG and SMUG
are divergent, but the active site pyrimidine binding pocket topol-
ogy is conserved. However, the mechanisms for thymine exclusion,
nucleotide ﬂipping, as well as interaction with the abasic site prod-
uct are different [10,65]. Originally thought to be restricted to
vertebrates, SMUG1 is now known to be present in prokaryotes
as well, but not in yeast. Interestingly, UNG and SMUG1  tend to be
mutually exclusive with respect to their presence in bacteria, sug-
gesting functional overlap in an evolutionary perspective [66,67].
Similar to Ung−/− mice, Smug−/− mice and even Ung−/−/Smug−/−
double knockouts are viable and fertile and without a distinct
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arly phenotype. However, Ung−/−/Smug−/−/Msh2−/−triple knock-
uts have a distinctly shortened lifespan compared with Msh2−/−
ice, suggesting that mismatch repair may  serve as an ultimate
ackup in repair of genomic uracil [68].
.3. BER of uracil in mutation prevention and the ﬁdelity of
ucleotide insertion
Although BER is considered highly accurate, errors may  occur
ue to replication across unrepaired base lesions or abasic sites and
ue to polymerase errors during gap ﬁlling. Unfortunately, there is
enerally little information on the fraction of base lesions left unre-
aired. The mutation rate in an UNG-deﬁcient human glioma cell
ine in a shuttle vector carrying a single uracil-residue was found
o be increased approximately 3-fold relative to control, with G:C
o A:T transitions being the most common substitution [69]. Some-
hat surprisingly, the spontaneous mutation frequencies in Ung−/−
ice in a lacI transgene and Big Blue background was only modestly
ncreased; 1.4-fold and 1.3-fold in spleen and thymus, respectively.
nterestingly, in spleen the mutations were largely due to muta-
ions at non-methylated C:G pairs, but in thymus ±1 frameshifts
ere predominant, suggesting a different mutational mechanism
56]. Nevertheless, the Ung−/− mice developed B-cell lymphomas
t a 20-fold increased frequency compared with wild type, with-
ut increase in other forms of cancer, indicating a speciﬁc and
mportant role of Ung in B-cells [70,71]. The mice also developed
onoclonal B-cell hyperplasia, suggesting hyperplasia as an early
tep in lymphomagenesis [70]. An analysis of gene-speciﬁc muta-
ion frequencies in lymph node tumors from Ung−/− mice revealed
 moderate 1.4 to 1.8-fold increase in Bcl-6 and c-Myc genes that are
on-canonical targets for AID. However, a large lymph node tumor
hat expressed very high constitutive levels of AID displayed 6- and
-fold increased levels of mutations in Bcl-6 and c-Myc loci, respec-
ively, but mutation frequencies were not increased in p53, which
s not an AID target. As expected, the C to T transition mutations
ere increased in Ung-deﬁcient mice relative to control [72]. Simi-
arly, a 5.2-fold increased mutation frequency at the Hprt locus was
bserved in Ung−/−MEFs. Importantly, a 2.4-fold increase in muta-
ion frequencies was also observed in SMUG1 knockdown MEFs,
ndicating that Ung2 and Smug1 could not fully complement each
ther. Furthermore, a 9.6-fold increase in mutation frequencies was
bserved in Ung−/−/Smug1 knockdown MEFs [73].
Although C to T transitions are the most common mutations in
hese studies, T to C transitions, as well as transversions, were not
nfrequent. Furthermore, ±1 indels were also relatively common.
ne possible source of ±1 indels could potentially be template
r primer slippage during gap ﬁlling. The ﬁdelity in nucleotide
nsertion during in vitro BER of uracil in extracts of DNA poly-
erase -proﬁcient and deﬁcient mouse embryonic ﬁbroblasts
emonstrated an error frequency of approximately 5–7 per 104
ucleotides, but with somewhat different proﬁles in the two cell
ypes [74]. A similar error frequency was observed for nucleotide
nsertion in extracts of E. coli [75]. Another study reported
lightly lower error-frequency of 1 to 6 per 104 deoxynucleotide-
nsertions during in vitro repair in extracts from proliferating and
on-proliferating human cells. Here the lowest error frequency was
bserved for U:A pairs in extracts from proliferating cells and the
ighest error frequency observed for U:G mismatches in extracts
rom non-proliferating cells. This difference could be ascribed to
he lower ﬁdelity of DNA polymerase  that lacks proof-reading
ctivity [25]. In these studies errors predominantly occurred at the
ite of the uracil. If the in vivo error rate in nucleotide insertion is
f the same order of magnitude as that measured in vitro, errors
n nucleotide insertion during BER may  actually be a signiﬁcant
ource of mutations, considering that the number of spontaneous
esions processed by BER is thought to be more than 104 perair 19 (2014) 38–47
day (reviewed in [2,76]). A one-nucleotide deletion at the site of
damage was a frequent error in these studies, suggesting template
slippage as a potential source. DNA polymerase  is another
family × polymerase. It may  substitute for DNA polymerase  in
repair of oxidative lesions, although it has a modest role [77]. Inter-
estingly, it was found that DNA polymerase  was generally more
error-prone than DNA polymerase  in vitro, particularly when
inserting dCTP at a gap size of 2 or more. Under some conditions,
DNA polymerase  was up to 160-fold more error-prone than DNA
polymerase  [78]. Another source of errors is translesion synthesis
over a lesion. In yeast, mutagenic translesion synthesis over natural
abasic sites in intact cells was  found to involve REV1 and DNA
polymerase  [79]. In these studies, abasic sites were generated by
expressing mutant uracil-DNA glycosylases that attacked normal
thymines or cytosines in DNA [7]. Earlier studies that used these
mutant UNG proteins to generate abasic sites in a panel of E. coli
DNA repair mutants demonstrated that BER, translesion synthesis
and homologous recombination were all contributing to the pro-
cessing of abasic sites [80]. Furthermore, expression of APOBEC3G
in yeast cells to create uracils in single stranded DNA  as substrate
for UNG, demonstrated that the sequence context strongly inﬂu-
enced the relative insertion by REV1 and DNA polymerase  of A
or C opposite the abasic site [81]. These studies demonstrate that
abasic site intermediates are both toxic and mutagenic and reveal
a complex processing that involves both BER, translesion synthesis
and, at least in E. coli, homologous recombination.
2.4. Roles of AID/APOBEC and UNG2 in adaptive and innate
immunity
The landmark discovery of AID as a trigger of adaptive immu-
nity has opened one of the last black boxes in immunology [82].
Originally AID was proposed to be an RNA-cytosine deaminase due
to sequence homology to RNA-cytosine deaminase APOBEC1 [82],
but was subsequently found to be a mutator when expressed in
E. coli, indicating that it could also be a DNA-cytosine deaminase
[83]. The mechanism for SHM and CSR was therefore proposed to
involve AID as a DNA-cytosine deaminase generating mutagenic
U:G mismatches, causing C to T transitions if replicated across,
and uracil-DNA glycosylase to generate abasic sites. These could
then be substrate for mutagenic translesion polymerases to gen-
erate a wider range of mutations, as well as substrate for strand
cleavage by an AP-endonuclease to initiate CSR (Fig. 2) [83]. Sev-
eral lines of evidence support this scheme. First, as mentioned, AID
was found to be a strong mutator when expressed in E. coli [83]
and was  demonstrated to be a single strand-speciﬁc DNA-cytosine
deaminase in vitro [84], especially in preferred sequence contexts
for SHM and CSR [85]. Second, Ung−/−mice display skewed SHM
and strongly reduced CSR [86]. Similarly, inactivating mutations
in the UNG gene in humans are associated with the hyper IgM syn-
drome and a profound impairment in CSR at the pre-cleavage stage.
Total lack of functional UNG-protein in humans, due to mutations
in both UNG-alleles, is a very rare condition that phenotypically
resembles AID-deﬁciency. It causes recurrent infections and lym-
phoid hyperplasia, supporting the important function of UNG in
adaptive immunity [87]. Third; the presence of uracil-residues has
been demonstrated in variable and switch regions of Ig-genes after
stimulation of B-cells [48]. Fourth; AID binds cooperatively with
UNG and Msh2-Msh6 to Ig switch regions and this depends on
the C-terminal end of AID [88]. Fifth; AID is recruited to Ig-switch
regions and non-Ig targets by the RNA polymerase II-associated
protein SPT5, which is required for CSR [89]. Sixth; a study on
nuclear import rate and DNA-cytosine deaminase activity of a panel
of AID mutants revealed a strong correlation between CSR and the
product of nuclear import rate and deaminase activity, as would be
expected for an enzyme carrying out its function on nuclear DNA
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Fig. 2. Mutagenic processing of genomic uracil generated by AID/APOBEC cytidine deaminases. Upper panels: single strand-selective AID initiates somatic hypermutation
(SHM)  at Ig loci in germinal centers of B-cells. SHM introduces mutations in variable regions and switch regions of Ig-genes. This is required to generate high afﬁnity
antibodies. In SHM, replication over U:G mismatches generates C to T transitions, whereas insertion of dCMP opposite abasic sites by REV1 is responsible for most C to G
transversions. Other TLS polymerases, e.g. POL and POL	, as well as mismatch repair proteins, are also involved in SHM (not shown). Uracilation of some DNA  viral genomes
and  retroviral DNA-intermediates creates substrates for their degradation as part of innate immune responses. However, untargeted action of AID/APOBEC may  cause a wide
range  of substitution mutations by mechanisms bearing resemblance to those of normal SHM. These are very likely to contribute to a wide range of human malignancies. The
lower  panels display features of normal class switch recombination (CSR) that bears some similarity to the mechanisms causing kataegis, characterized by clustered, strand
s e clea
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pelective mutations in the vicinity of genomic rearrangements. In CSR, Ig-genes ar
his  allows joining of Ig-gene variable regions and alternative effector regions by N
rocess leading to double strand breaks resulting in genomic rearrangements and t
90]. In sum, these lines of evidence, and numerous other reports,
trongly support the DNA-deamination model. Furthermore, to
ur knowledge there are no reports demonstrating RNA-cytosine
eamination by AID, although it binds RNA, apparently without
electivity [84]. Although an important role of UNG in CSR is undis-
uted, the requirement for UNG activity in CSR was  challengedved at switch regions by a process requiring AID, UNG2, APE1 and other proteins.
roteins. Kataegis also requires AID/APOBEC and UNG2, probably both to initiate the
rate substrates for strand selective mutations by TLS.
by the observation that catalytically impaired mutants of UNG
could complement Ung−/− mice in CSR, suggesting a structural role
rather than catalytic role of UNG [91]. Although these mutants were
catalytically strongly impaired, they were overexpressed and not
catalytically dead [8]. Since UNG-proteins have very high turnover
numbers compared with other DNA glycosylases [59], it is possible
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hat the residual activity is sufﬁcient to support CSR. However, a
tructural role of nuclear UNG (UNG2) in a repair or mutagene-
is complex cannot be ruled out, since UNG2 has many interaction
artners [54,55,92], and since a structural role has been indicated
n subsequent experimental work on the mechanism of CSR [93].
POBEC1 was originally identiﬁed as an Apolipoprotein B mRNA
diting enzyme that deaminated a speciﬁc cytosine residue, gener-
ting a stop codon and therefore a shorter form of ApoB. APOBEC1
nd several other APOBEC proteins were subsequently shown to
e DNA-cytosine deaminases as well [94]. Several of the APOBEC3
amily members have been shown to have a role in the defense
gainst retrovirus infection as part of the innate immune response.
ere, APOBEC3 protein deaminates cytosine residues to uracil in
he retroviral DNA intermediate, which is then attacked by UNG-
ncoded uracil-DNA glycosylase, followed by viral DNA degrada-
ion (Fig. 2) [45]. Furthermore, a role of APOBEC3 in editing (muta-
ion) of human papilloma virus in precancerous lesions has been
eported [95]. Interestingly, cervical cancers, known to be caused by
uman papilloma viruses, carry a pronounced APOBEC mutational
ignature [96]. In conclusion, AID/APOBEC proteins and nuclear
NG2 have important roles both in adaptive and innate immunity.
. AID and other APOBEC proteins cause cancer with U:G
ismatches as likely basis for mutations
.1. Hematological malignancies
Dysregulated SHM and CSR is the likely cause of a substantial
raction of B-cell malignancies. A hallmark of B-cell lymphomas is
he presence of chromosomal translocations between the Ig-locus
nd a proto-oncogene [97]. Speciﬁc translocations are associated
ith selected subtypes of B cell lymphomas, such as the bcl-1/Ig
ranslocation in Mantle zone lymphoma, bcl-2/Ig translocation in
ollicular lymphoma, and c-myc/Ig translocation in Burkitt’s lym-
homa [98]. Removal of AID decreases translocations between
-myc and the IgH variable region, suggesting that AID is required
or this translocation [99]. AID-induced chromosomal breaks and
earrangements with IgH and MYC  occur more frequently at
ranscription start sites, consistent with transcription-coupled
eamination of single stranded DNA [100]. AID shifts the incidence
rom pre-B cell to more mature B cell lymphomas in c-Myc-
verexpressing transgenic mice [101] and shifts the preference
rom Mantle cell lymphoma to diffuse large B-cell lymphomas in
CL6-overexpressing transgenic mice, suggesting that AID deam-
nation during antibody maturation in germinal centers may  be
ymphomagenic [102]. Importantly, AID knockouts acquire signiﬁ-
antly less mutations in several genes linked to B cell tumorigenesis,
hile UNG and MSH2 protect against such AID induced mutations
103]. The role of AID may  not be limited to early lymphomagene-
is, as AID is highly expressed in several lymphomas from patient
amples [104–106]. In human patient samples, AID expression in
ollicular lymphomas is correlated with ongoing mutation [107].
owever, the extent to which this AID expression confers a signif-
cant mutator phenotype contributing to cancer progression and
oor prognosis is a matter of debate [108–110]. In conclusion, a
ole of AID as a mutator protein in B-cell malignancies is well doc-
mented from animal experiments and human disease. DNA repair
roteins may  apparently both prevent mutations and contribute to
utagenic effects of AID.
.2. Other malignanciesHigh-throughput sequencing has made possible analysis of
hole cancer genomes and exomes from large numbers of differ-
nt cancer types [96]. This strategy has identiﬁed genes that are
ikely to be involved in transformation of normal cells to cancer cellsair 19 (2014) 38–47
and has identiﬁed mutational signatures that reveal their probable
origin (Fig. 2). Mutations at cytosine-residues are by far the most
common type of mutation in human cancer, with C → T transitions
being the most prevalent change [111]. Following the discovery
that AID is a DNA-cytosine deaminase [83,84], it was  reported that
8 out of 10 other APOBEC proteins are also DNA-cytosine deami-
nases, including APOBEC1, APOBEC3B, APOBEC3C, APOBEC3G and
others [45,94]. Furthermore, the predominantly nuclear APOBEC3B
is expressed in most primary breast tumors and breast cancer cell
lines and causes increased genomic levels of uracil, which was
reduced by shRNA knockdown of APOBEC3B [112]. This suggests
that mutagenic U:G mismatches in DNA may  be a fundamental
cause of a signiﬁcant fraction of breast cancers. Furthermore, exome
or complete genome sequencing of more than 7000 human cancers
identiﬁed mutational signatures with probable APOBEC association
for 16 out of 30 different primary cancer types [96]. Although these
tumors always carried more than one mutational signature, indi-
vidual cancers of a certain type with a particularly high number
of mutations were frequently dominated by an APOBEC signa-
ture, when excluding those with a strong environmental exposure
(melanoma and lung cancer). APOBEC signatures were observed
in e.g. cancers of bladder, breast, cervix, thyroid, lung adenocarci-
noma, squamous cell lung cancer, acute lymphoblastic leukemia,
B-cell chronic lymphocytic leukemia, B-cell lymphomas and mul-
tiple myeloma [96]. An APOBEC signature was void in several other
cancer forms, e.g. colorectal cancer, liver cancer, acute myeloid
leukemia and in some cancer forms associated with heavy carcino-
gen exposure, e.g. melanoma and small cell lung cancer [96].
APOBEC-induced mutational signatures are characterized by the
simultaneous occurrence of C → T transitions, C → G transversions
and a lower number of C → A transversions, all occurring particu-
larly in TCA, TCC, TCG and TCT sequence contexts [96]. The C → T
transitions probably mostly occur due to replication over U:G mis-
matches that have not been processed. The C → G transversions
may be caused by translesion bypass over an abasic site by REV1
and DNA polymerase  resulting from base removal by UNG2, as
indicated from yeast experiments [79,113]. The yeast studies also
observed that a smaller number of C → A transversions occurred as
a consequence of generation of abasic sites in yeast, the mechanism
of which is not clear [79].
3.3. Kataegis—Localized hypermutations in malignancies
One novel observation in the cancer genome studies is the
presence of localized, regional hypermutations in one strand and
associated genomic rearrangements (Fig. 2). This phenomenon has
been coined kataegis from a Greek word for rainfall [96,114,115].
The sequence contexts and mutation patterns in kataegis in most
cancer types suggest an association with APOBEC3 enzymes, with
enrichment at TpCpN sequences and a predominant occurrence of
C → T transitions and C → G transversions [96]. A mutation pat-
tern mimicking kataegis was induced experimentally in yeast by
expressing PmCDA1, a mutagenic cytosine deaminase from sea
lamprey [116], or AID/APOBEC3B [117]. Interestingly, deﬁciency in
either UNG or REV1 strongly decreased transversions. Furthermore,
UNG-deﬁciency resulted in a 4-fold increase in total mutations,
but reduced kataegis substantially [117]. The reduction in the total
mutations by UNG, but strong dependence of UNG for localized
hypermutation is another manifestation of the dual role of UNG,
presumably UNG2, as both anti-mutator and mutator.
4. Some thoughts on future perspectivesDuring the last decade extensive and complex interactions
between mechanisms of genome integrity and immunity have
increasingly become apparent. In fact, proteins from all major DNA
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epair pathways, apparently except nucleotide excision repair, con-
ribute positively to adaptive immunity. The less bright side is
hat DNA-cytosine deaminases in co-operation with DNA repair
roteins may  cause untargeted point mutations, genomic rear-
angements and a wide range of cancers, with U:G mismatches
s a fundamental starting point (Fig. 2). To understand these non-
anonical roles of AID/APOBEC and DNA repair proteins will require
ubstantial efforts in the future and will undoubtedly be a major
esearch area. This would also comprise a better understanding of
ow AID/APOBEC proteins are induced under normal and patholog-
cal conditions. Numerous articles have demonstrated expression
f AID/APOBEC in different tissues in response to infectious agents
both virus and bacteria) and other inﬂammatory conditions, while
nterferons are strong intracellular inducers of expression. Perhaps
s this an important link between inﬂammation and cancer. How-
ver, since a fraction of tumors and tumor cell lines constitutively
xpress AID (B-cell lymphomas) and APOBEC proteins (e.g. breast
umors), mutations in regulatory regions of in these genes, or genes
egulating their normal expression would also appear to be likely,
ut has apparently not yet been explored.
The mechanisms that govern error-free versus mutagenic pro-
essing of U:G mismatches remain obscure and need to be
ddressed. UNG1 (mitochondrial) and UNG2 (nuclear) remove
racil from both single stranded DNA, U:A and U:G contexts. But
e do not know whether these are further processed by the
ame or different set or complex of proteins. Post-translational
odiﬁcations may  also be candidates to switch pathways [118].
urthermore, we do not know whether the damage-initiating
gent dictates subsequent steps. As an example, a different set of
rocessing proteins may  be recruited to genomic uracil in enzyme-
enerated U:G mismatches as compared to U:G mismatches arising
rom spontaneous deamination or U:A from replication errors. It is
lso likely that the chromatin structure may  inﬂuence recruitment
f the damage-processing proteins, as well as their access to the
amage.
Strong APOBEC mutational signatures in the cancer genome may
ndicate that APOBEC protein has been expressed over a substan-
ial period of time, resulting in a distinct signature and frequently
 high number of mutations. The ﬁnding that persistent APOBEC
r AID expression has been measured in a large fraction of breast
umors and B-cell malignancies would support this notion. How-
ver, it is difﬁcult to see that continued expression would give a
asting selective advantage to the tumor cells. Rather, one might
hink that once a cell has been transformed to a precancerous or
ancer cell phenotype, continued expression of AID/APOBEC would
e a disadvantage. It is possible that AID/APOBEC proteins may  have
een involved in transformation in an early, but critical shorter
eriod, even in the absence of a strong APOBEC signature in the
alignant cell end point.
Non-canonical functions of DNA repair proteins have come as
 surprise, but are rather extensive [119,120]. Perhaps we  should
ot be surprised. Dual or multiple functions of proteins may  seem
o be a rule rather than an exception.
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